Skip to main content
Journal cover image

Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.

Publication ,  Journal Article
Pun, PH; Al-Khatib, SM; Han, JY; Edwards, R; Bardy, GH; Bigger, JT; Buxton, AE; Moss, AJ; Lee, KL; Steinman, R; Dorian, P; Hallstrom, A ...
Published in: Am J Kidney Dis
July 2014

BACKGROUND: The benefit of a primary prevention implantable cardioverter-defibrillator (ICD) among patients with chronic kidney disease is uncertain. STUDY DESIGN: Meta-analysis of patient-level data from randomized controlled trials. SETTING & POPULATION: Patients with symptomatic heart failure and left ventricular ejection fraction<35%. SELECTION CRITERIA FOR STUDIES: From 7 available randomized controlled studies with patient-level data, we selected studies with available data for important covariates. Studies without patient-level data for baseline estimated glomerular filtration rate (eGFR) were excluded. INTERVENTION: Primary prevention ICD versus usual care effect modification by eGFR. OUTCOMES: Mortality, rehospitalizations, and effect modification by eGFR. RESULTS: We included data from the Multicenter Automatic Defibrillator Implantation Trial I (MADIT-I), MADIT-II, and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 2,867 patients were included; 36.3% had eGFR<60 mL/min/1.73m2. Kaplan-Meier estimate of the probability of death during follow-up was 43.3% for 1,334 patients receiving usual care and 35.8% for 1,533 ICD recipients. After adjustment for baseline differences, there was evidence that the survival benefit of ICDs in comparison to usual care depends on eGFR (posterior probability for null interaction P<0.001). The ICD was associated with survival benefit for patients with eGFR≥60 mL/min/1.73 m2 (adjusted HR, 0.49; 95% posterior credible interval, 0.24-0.95), but not for patients with eGFR<60 mL/min/1.73 m2 (adjusted HR, 0.80; 95% posterior credible interval, 0.40-1.53). eGFR did not modify the association between the ICD and rehospitalizations. LIMITATIONS: Few patients with eGFR<30 mL/min/1.73 m2 were available. Differences in trial-to-trial measurement techniques may lead to residual confounding. CONCLUSIONS: Reductions in baseline eGFR decrease the survival benefit associated with the ICD. These findings should be confirmed by additional studies specifically targeting patients with varying eGFRs.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Kidney Dis

DOI

EISSN

1523-6838

Publication Date

July 2014

Volume

64

Issue

1

Start / End Page

32 / 39

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Risk Factors
  • Renal Insufficiency, Chronic
  • Randomized Controlled Trials as Topic
  • Primary Prevention
  • Patient Readmission
  • Middle Aged
  • Male
  • Kaplan-Meier Estimate
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pun, P. H., Al-Khatib, S. M., Han, J. Y., Edwards, R., Bardy, G. H., Bigger, J. T., … Sanders, G. D. (2014). Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis, 64(1), 32–39. https://doi.org/10.1053/j.ajkd.2013.12.009
Pun, Patrick H., Sana M. Al-Khatib, Joo Yoon Han, Rex Edwards, Gust H. Bardy, J Thomas Bigger, Alfred E. Buxton, et al. “Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.Am J Kidney Dis 64, no. 1 (July 2014): 32–39. https://doi.org/10.1053/j.ajkd.2013.12.009.
Pun PH, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, et al. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis. 2014 Jul;64(1):32–9.
Pun, Patrick H., et al. “Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.Am J Kidney Dis, vol. 64, no. 1, July 2014, pp. 32–39. Pubmed, doi:10.1053/j.ajkd.2013.12.009.
Pun PH, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Hess PL, Inoue LYT, Sanders GD. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis. 2014 Jul;64(1):32–39.
Journal cover image

Published In

Am J Kidney Dis

DOI

EISSN

1523-6838

Publication Date

July 2014

Volume

64

Issue

1

Start / End Page

32 / 39

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Risk Factors
  • Renal Insufficiency, Chronic
  • Randomized Controlled Trials as Topic
  • Primary Prevention
  • Patient Readmission
  • Middle Aged
  • Male
  • Kaplan-Meier Estimate
  • Humans